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• Robust preparation of liposomal for-
mulation by DELOS-susp method.
• Implementation of Quality by Design
methodology to liposomes preparation.
• Influence of critical parameters on
quality was studied through DoE ana-
lysis.
• Design Space was obtained for GLA-
loaded liposomes formulation.
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A B S T R A C T
Fabry disease is a lysosomal storage disease arising from a deficiency of the enzyme α-galactosidase A (GLA).
The enzyme deficiency results in an accumulation of glycolipids, which over time, leads to cardiovascular,
cerebrovascular, and renal disease, ultimately leading to death in the fourth or fifth decade of life. Currently,
lysosomal storage disorders are treated by enzyme replacement therapy (ERT) through the direct administration
of the missing enzyme to the patients.
In view of their advantages as drug delivery systems, liposomes are increasingly being researched and utilized
in the pharmaceutical, food and cosmetic industries, but one of the main barriers to market is their scalability.
Depressurization of an Expanded Liquid Organic Solution into aqueous solution (DELOS-susp) is a compressed
fluid-based method that allows the reproducible and scalable production of nanovesicular systems with re-
markable physicochemical characteristics, in terms of homogeneity, morphology, and particle size. The objective
of this work was to optimize and reach a suitable formulation for in vivo preclinical studies by implementing a
Quality by Design (QbD) approach, a methodology recommended by the FDA and the EMA to develop robust
drug manufacturing and control methods, to the preparation of α-galactosidase-loaded nanoliposomes
(nanoGLA) for the treatment of Fabry disease.
Through a risk analysis and a Design of Experiments (DoE), we obtained the Design Space in which GLA
concentration and lipid concentration were found as critical parameters for achieving a stable nanoformulation.
This Design Space allowed the optimization of the process to produce a nanoformulation suitable for in vivo
preclinical testing.
1. Introduction
One of the main challenges to produce advanced materials such as
enzyme-loaded liposomes is the successful implementation of new
manufacturing nanotechnologies at industrial scale. The DELOS-susp
method is a compressed fluid-based technology that allows the re-
producible preparation of different nanovesicular systems with re-
markable physicochemical characteristics, in terms of homogeneity,
morphology and particle size, as well as a high versatility to integrate
different active compounds, that can lead to innovative nanomedicines
with enhanced efficiency [1–3].
Lysosomal storage disorders (LSD) are diseases caused by lysosomal
dysfunction usually as a consequence of deficiency of a single metabolic
enzyme. In the case of Fabry disease, the lack of α-galactosidase A
(GLA) enzyme causes the accumulation of glycosphingolipids leading to
multiple organ pathology [4]. Enzyme replacement therapy (ERT),
which is the main current treatment, exhibits several drawbacks mainly
related to protein instability and low efficacy [5].
To overcome the main limitations of the current ERTs (e.g. rapid
enzyme degradation, high immunogenicity, short circulation half-life,
poor biodistribution, and limited efficacy among others [6]) a strategy
under development consists in the encapsulation of the GLA enzyme
into nanoliposomes. Such encapsulation aims to protect the enzyme,
decrease the degradation and immunogenicity of GLA, and increase its
plasma half-life. Moreover, the addition of a targeting peptide on the
liposomal membrane can facilitate cellular up-take via peptide re-
ceptors recognition and could help to improve GLA biodistribution.
Thus, GLA-loaded nanoliposomes (nanoGLA) functionalized with Ar-
ginine-Glycine-Aspartic acid (RGD) peptide and prepared by DELOS-
susp, have recently been reported to increase enzymatic activity and
intracellular penetration, showing the great potential of this CO2-based
methodology for the simple production of protein-nanoliposome ther-
apeutic conjugates [4,7]. Fig. 1 shows the DELOS-susp process and the
starting materials used to obtain the nanoGLA liposomal formulation.
The results obtained in earlier stages of nanoGLA development, al-
though being biocompatible and showing interesting in vitro activity,
presented some limitations regarding formulation characteristics for
continuing with their translation towards the clinics. In first place, the
concentration of GLA enzyme we could load into the nanoliposomes,
with robust particle size and PdI, was around 20 µg/mL, far below the
minimum required for reaching those doses that will allow to perform
efficacy studies in mice (200 µg/mL). Besides, the enzyme entrapment
efficiency in the liposomes was below 40% [4]. The addition of cationic
surfactant myristalkonium chloride (MKC) into the formulation in low
concentration allowed to increase the drug entrapment efficiency as
well as the colloidal stability of the system [7]. However, further work
was required in order to obtain a stable formulation with the proper
protein concentration.
In this work we applied the Quality by Design (QbD) approach to
determine formulation and process parameters that could have an
important impact on nanoGLA attributes when prepared by DELOS-susp.
The QbD methodology is described in Guidelines of the International
Council for Harmonisation of Technical Requirements for Pharmaceuticals
for Human Use (ICH) [8–10] and it is strongly encouraged by the Food and
Drug Administration (FDA) and the European Medicines Agency (EMA) to
develop robust drug manufacturing and control methods. Pharmaceutical
QbD is a systematic approach to development that aims to ensure the
quality of medicines, identifying characteristics that are critical to quality
from the patient’s perspective, translating them into the product Critical
Quality Attributes (CQAs), and establishing a relationship between man-
ufacturing variables and CQAs through a Design of Experiments (DoE).
The goals of the pharmaceutical QbD may include the achievement of
meaningful product quality specifications as well as the reduction of
product variability and defects, to increase efficiencies and to enhance root
cause analysis [11].
Another systematic methodology used in pharmaceutical design is
the Safe by Design (SbD) approach, which aims to eliminate possible
risks to the human health and the environment at early innovation
stages, i.e., during the design or planning stage [12]. SbD requires a full
life cycle perspective combined with nanomaterial sustainability
(environmental, social, and economic) [13] improvements, to avoid the
shifting of potential risks across development stages.
In this framework, we report here the implementation of the QbD
approach to develop a robust process for the preparation of nanoGLA. In
the present work, the process was scaled-up from previous work [4] by a
7-fold factor, and the liposomal prototype was optimized increasing
10-times (i.e. from around 20 to 200 µg/mL) the final concentration of
GLA enzyme in the nanoformulation. Its physicochemical stability was
improved while meeting the defined quality specifications in order to
fulfill the required therapeutic doses for advanced preclinical testing.
Besides, a SbD evaluation of the nanoGLA manufacturing process by
DELOS-susp is also presented.
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2. Materials and methods
2.1. Materials
GLAcmycHis protein (GLA) was synthetized as explained in
Appendix A. 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) was
purchased from Corden Pharma (Liestal, Switzerland), cholesterol was
purchased from Panreac Química (Castellar del Vallès, Spain), and myr-
istalkonium chloride (MKC) from United States Biological (Salem, US).
Cholesterol pegylated with arginyl–glycyl–aspartic acid peptide
(Chol-PEG400-RGD) was synthetized as described by E. Cristóbal-Lecina
et al. [14]. Ethanol (EtOH) was purchased from Scharlab (Sentmenat,
Spain), dimethyl sulfoxide (DMSO) from Sigma-Aldrich (St. Louis, US),
carbon dioxide (CO2) and nitrogen (N2) from Carburos Metálicos
(Cornellà de Llobregat, Spain). Diafiltration column modules of
300 kDa cut-off were purchased from Repligen (Waltham, US). Ultra-
pure Type I water (H2O), purified using Milli-Q Advantage A10




DELOS-susp methodology was used for the nanoGLA preparation
(Fig. 1). An EtOH:DMSO solution (volume ratio EtOH:DMSO 4:1) con-
taining DPPC (from 0.86 to 3.46mg/mL), cholesterol (from 0.30 to
1.24mg/mL), Chol-PEG400-RGD (from 0.03 to 0.31mg/mL), and MKC
(from 0.02 to 0.07mg/mL) at a working temperature (Tw) of 308 K was
loaded into a 50mL high pressure vessel at atmospheric pressure. The
solution was, then, volumetrically expanded with compressed CO2 until
a molar fraction (XCO2) of 0.55 was achieved, reaching a working
pressure (Pw) of 9MPa. The system was kept at 308 K and 9MPa under
stirring for approximately 15min to achieve a complete homogeniza-
tion and to attain thermal equilibration. A given volume of GLA stock
solution at 0.28mg/mL, measured by SDS-PAGE, was dissolved in ul-
trapure water to reach the desired enzyme concentration (7, 17 or
27 µg/mL). To form the nanoconjugates, the volumetrically expanded
organic phase was depressurized over the aqueous solution containing
the GLA. In this way, nanoGLA DELOS-susp batches of 290–500mL
were obtained. In this step, a flow of compressed N2 was used as a
plunger to push down the CO2‐expanded solution from the vessel and to
maintain a constant pressure of 10MPa inside the vessel during de-
pressurization. Average time per experiment was 60min and the re-
sulting dispersions of nanoconjugates were stored at 4 °C until their
characterization. The process parameters that were kept constant for all
experiments are listed in Appendix B.
2.2.2. Separation of the free GLA from the nanoGLA liposomal dispersion
by diafiltration and concentration process
The non-conjugated GLA enzyme (with a molecular weight between
90 and 110 kDa in its dimer form) was separated from the GLA-loaded
liposomes obtained by DELOS-susp using a KrossFlo Research IIi
Tangential Flow Filtration (TFF) System with mPES hollow fiber mod-
ules of 300 kDa cut-off, in order to determine the GLA entrapment ef-
ficiency (EE) [4]. A volume of 10mL of liposomal sample was added to
the sample container, which was connected to the column and the
buffer reservoir. Six diafiltration cycles were performed with ultrapure
Type I water to eliminate the free molecules and the organic solvent
present in the liposomal samples.
Concentration of the intermediate nanoGLA during the optimization
step was performed using the same equipment, materials, and condi-
tions. A volume of 50mL of diafiltrated sample was added to the sample
container and submitted to a 7.5 concentration factor, evacuating ca.
87% of water.
Fig. 1. Schematic representation of the
DELOS-susp method for the preparation of GLA
loaded nanoliposomes (nanoGLA). The proce-
dure includes: a) Loading of an organic solu-
tion containing the liposome membrane com-
ponents (Cholesterol, DPPC, Cholesterol-
PEG400-RGD, MKC) into the high pressure
vessel; b) Addition of compressed CO2 until a
certain pressure to produce a CO2-expanded
solution, where all membrane components re-
main dissolved in a single liquid phase; and c)
Depressurization of the expanded solution over
an aqueous solution containing the GLA en-
zyme at atmospheric pressure, obtaining the
protein-liposomes nanoconjugates.
Figure adapted from [4].
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2.2.3. Characterization of liposomes
2.2.3.1. Mean particle size, PdI and ζ-potential. Liposomal mean size,
polydispersity index (PdI) and ζ-potential were determined by Dynamic
Light Scattering (DLS), using a Zetasizer Nano ZS analyzer (Malvern
Instruments, Malvern, UK). The measurements were performed at 20 °C
with a scattering angle of 173°, immediately after liposomes’ preparation,
and 1 and 2 weeks after the production.
2.2.3.2. Turbiscan Stability Index. Turbiscan Stability Index (TSI) was
determined by Static Multiple Light Scattering (S-MLS), using a
Turbiscan Lab Expert (Formulaction, Toulouse, France), at 20 °C and
2 weeks after liposomes production.
2.2.3.3. Morphology. The morphology of the systems was studied using
Cryogenic Transmission Electron Microscopy (Cryo-TEM). Images were
obtained with a FEI Tecnai G2 12 microscope (FEI, The Netherlands)
operating at 120 kV, as described in [15]. The analysis was performed 1
week after samples production.
2.2.3.4. Uni-lamellarity. Quantitative information on the liposomes
degree of lamellar structure and bilayer thickness was investigated
with small-angle X-ray scattering (SAXS) on an optimized NanoSTAR
SAXS instrument (Bruker AXS, Karlsruhe, Germany) equipped with a
liquid Ga metal jet X-ray source (Excillum AB, Sweden) and scatterless
slits. The wavelength was λ=1.34 Å and the measurements were
performed 1 week after production. The data were analyzed by a model
similar to the one described in [16,17]. The model was expressed so
that the fraction of bilayers presented as single-layered vesicles, fsingle,
was a fit parameter.
2.2.3.5. Entrapment efficiency. The entrapment efficiency (EE) was
determined by comparing the amount of enzyme encapsulated in the
nanovesicles after removal of free enzyme by diafiltration (Loaded
prototype) with the amount of initial GLA present in the DELOS-susp






To detect and quantify the enzyme in each of these samples, SDS-
PAGE was performed by using gels TGX Stain-Free™ FastCast™ acryla-
mide 12% (Bio-Rad, ref. 161-0185). To visualize the fluorescent bands,
a ChemiDoc™ Touch Imaging System (Bio-Rad) was used. Samples and
standards to be quantitatively compared were run in the same gel and
processed as a set. Densitometric analysis of the bands were performed
with the Image Lab™ software (version 5.2.1., Bio-Rad).
Fig. 2. Process Flow Diagram to produce the nanoGLA. Raw materials and the materials leaving the process are also represented. In red, the intermediate nanoGLA
formulation obtained by DELOS-susp that has been studied in the QbD implementation. Diafiltration and concentration processes are necessary to remove the
remaining free GLA and organic solvents from the nanoformulation and to maximize the enzyme concentration in the final nanoformulation for preclinical studies,
respectively.
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2.2.3.6. Enzymatic activity. The α-galactosidase specific enzymatic
activity (EA) of liposomal formulations was assayed using
4-Methylumbelliferyl α-D-galactopyranoside (4-MUG, Sigma Chemical)
as substrate, at a concentration of 2.46mM in assay buffer (0.01M acetic
acid, pH 4.5) as previously described [18]. The released product
(4-methylumbelliferone) was determined by fluorescence measurement
(λexc = 365, λem = 450 nm) and final specific enzymatic activities
were shown as 4-methylumbelliferone μmol per time and protein
quantity. Measurements were performed 1 week after production of
the samples.
2.2.4. Experimental design and data processing
An experimental design with 4 factors at 2 levels with 2 central
points (resulting in a total of 10 experimental runs) was constructed in
order to study the influence of formulation parameters (independent
variables or factors) on the properties (dependent variables or re-
sponses) of nanoGLA dispersion. The selected experimental design was
a Fractional Factorial design, and it was developed using Modde 12 Pro
software (Umetrics, Sweden). Data fitting and calculation of statistical
parameters were performed by partial least squares (PLS) method. The
experimental design used in this study allowed fitting the data with a
linear regression interaction model. The acceptance of the responses
obtained was evaluated by means of the statistical parameters predicted
by the software R2, Q2 model validity, and model reproducibility. The
design space for nanoGLA was determined using Design Space Explorer
option from the Optimizer module of Modde 12 Pro software.
3. Results and discussion
The process flow diagram of the whole nanoGLA optimized manu-
facturing process is presented in Fig. 2. Membrane components, sol-
vents, and gases, as well as the GLA protein, were processed using
DELOS-susp (see Section 2) obtaining an intermediate nanoGLA dis-
persion, whose quality was studied by QbD. Then, the optimized in-
termediate nanoGLA was diafiltrated and concentrated by TFF in order
to remove the organic solvents and to reach the target enzyme
concentration, which cannot be directly achieved in the DELOS-susp
step because of the limited solubility of the liposome membrane com-
ponents in the organic phase, while keeping the nanoformulation
quality.
3.1. Identification of the Critical Quality Attributes (CQAs)
During the development of liposomal drug products, the identifi-
cation and pertinent characterization of CQAs of liposomal drug
products is one of the main challenges from the quality point of view,
together with the definition of proper control strategies. Liposomal
products are complex formulations and small changes in their physi-
cochemical attributes can have notable effects in their in vivo perfor-
mance. Thus, a suitable definition of CQAs and control strategies may
allow a faster and more efficient drug product development [19].
Table 1 shows the CQAs selected for QbD implementation related to the
intermediate nanoGLA liposomal dispersion. The definition of the
quality attributes has considered the ICH recommendations, as well as
FDA and EMA guidelines [10].
As a parenteral dosage form, liposomal products must be sterile and
pyrogen-free. These parameters are not considered as CQAs at this stage
of formulation development since it is an intermediate product, but
they must be considered as CQAs in the final formulation.
3.2. Risk assessment and control strategies
Risk assessment is a valuable science-based process used in quality risk
management that can aid in identifying which material attributes and
process parameters potentially influence product CQAs [11,22]. The
potential risk factors which might influence the quality of the product
were identified through risk analysis, creating the Ishikawa diagram for
each CQA defined for nanoGLA (see Appendix C, where the detailed risk
analysis assessment is presented). As a result, 4 formulation factors were
considered relevant to be included in the subsequent DoE analysis: GLA
concentration, lipid concentration, peptide content in the liposomal
membrane, and ethanol concentration. The justification regarding the
Table 1
CQAs defined for the intermediate nanoGLA liposomal dispersion obtained by DELOS-susp and their justification.
Quality Attribute Justification [19–21]
Macroscopic Appearance It must be a homogeneous opalescent dispersion without sedimentation. Sedimentation could indicate poor
colloidal stability.
Mean Particle Size Particle size and particle size distribution are major CQAs for nanoparticle-based systems, playing an important
role in determining their in vivo absorption and distribution, drug loading, drug release, and targeting ability.
Therefore, robust control of particle size is one of the crucial parameters for further in vivo application of
liposomal drug products. Values below 300 nm are considered acceptable for nanoGLA.
Polydispersity Index (PdI) PdI reflects the heterogeneity of the particle size, indicating how wide is the particle size distribution. The lower
the PdI, the higher the homogeneity of the dispersion. To meet specification, PdI should be below 0.45.
ζ-potential Important parameter in the evaluation of colloidal system’s stability. Particles with a high negative or positive ζ-
potential value repel each other, indicating that the colloidal system is stable. On the contrary, decreasing the ζ-
potential value to nearly neutral could lead to liposomal aggregation. The liposome surface charge can also
influence drug loading, cellular uptake, tissue distribution, and clearance. ζ-potential values higher than
+ 30mV are considered inside the specification range for nanoGLA.
Particle morphology and lamellarity Vesicles must be spheroidal and, mostly, uni-lamellar. Lamellarity can affect drug loading and release, thus,
impacting the enzyme delivery.
GLA Entrapment Efficiency (EE) /Free drug substance Free drug substance may have side effects and impact into pharmacokinetic profile. Besides, a high and
reproducible percentage of drug entrapment could reduce manufacturing costs and increase drug concentration
in the final formulation allowing greater flexibility in dosing. Depending on the pharmacokinetics, higher drug
concentration can result in increased dosing intervals and hence improved patient compliance.
Specific Enzymatic Activity (EA) The bioactivity of the integrated enzyme must be preserved in the nanoformulation. EA ratio to control should
be higher than 0.8, referred to the EA of a commercially available GLA (agalsidase alfa, Replagal®).
Integration efficiency of Chol-PEG400-RGD in the
vesicular membrane
The amount of targeting peptide moiety integrated in the nanoliposomal membrane must be in the proper ranges
to allow the nanoGLA to interact with cells and facilitate intracellular penetration.
pH pH can affect dispersion stability, drug loading and release, and cell uptake among others. A suitable pH range is
from 6.0 to 7.0.
Dispersion stability The intermediate formulation must be stable at least until the diafiltration and concentration step. In terms of
Turbiscan stability, the TSI should be less than 10.0 at 24 h.
Lipid and GLA degradation products Chemical stability of the lipid components in the liposome as well as the chemical stability of the contained drug
substance is important. These will be considered at further stages of development.
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selection of these factors and their range of investigation is detailed in
Table 2.
Although the depressurization flow rate during the DELOS-susp
could be considered as a factor [30], it was not included in the present
work since an accurate flow rate range variation could not be carried
out in the used set-up. Due to limitations of the available in-house
synthesized starting materials (GLA and Chol-PEG400-RGD), an inter-
mediate laboratory plant was selected for performing the DoE. Thus, for
this first QbD study the depressurization flow rate was kept constant at
6.3 ± 0.7 g/min because it can be controlled within narrow values
where the formulation requirements are ensured. So, despite not being
able to introduce the flow rate as a factor in the present study, this
parameter was defined as a controlled variable that was kept constant
for all experiments. QbD is based on the principle of continuous im-
provement, thus, by gathering knowledge during early development, it
is possible to avoid potential manufacturing problems as the drug
product evolves through the development pipeline. Thus, the knowl-
edge obtained in the present study will allow to concisely define further
scale-up studies. The influence of DELOS-susp depressurization flow
rate variation on the nanoGLA quality will be more accurately eval-
uated in future studies at pilot plant scale, where it is possible to control
and register this parameter. Taking the present results as the basis for
refining the Design Space of the nanoGLA will ease this transition from
the lab to the pilot plant.
3.3. Experimental design and development
An experimental design was constructed to study the influence of
the formulation (independent variables or factors) on the physico-
chemical properties (dependent variables or responses) of intermediate
nanoGLA obtained by DELOS-susp, as shown in Table 3. Low and high
levels for each factor (Table 2) were selected based on previous ex-
periments and studies [4,7].
All process parameters, including depressurization flowrate at
10 g/min, were kept constant for all experiments. The responses of the
experimental design were the CQAs of the intermediate nanoGLA dis-
persion: particle mean size, polydispersity index, ζ-potential, Turbiscan
stability index, ratio of monolayered liposomes, entrapment efficiency,
enzymatic activity, and pH. Furthermore, macro and microscopic ap-
pearance (i.e. particle morphology) were analyzed, but these two CQAs
were not included in the design because of their qualitative nature. The
matrix of the experimental design is presented in Table 3.
All experiments were produced following DELOS-susp method at the
laboratory scale, as explained in Section 2. All 10 experiments were
produced in 2 consecutive days.
3.4. Characterization of the intermediate nanoGLA obtained
A high variability on the stability of the samples was observed
among the different experimental conditions tested. Thus, some char-
acterizations were performed at the production day (t= 0) and fol-
lowed until 14 days.
Regarding the macroscopic appearance, all DELOS-susp batches
presented a homogenous, whitish, opalescent appearance without pre-
sence of sediment, except for DOE-001, DOE-006, and DOE-009.
A summary of the microscopy analysis of the nanoGLA samples by
cryo-TEM is presented in Fig. 3, indicating that for all experiments
nanovesicles were obtained, being mostly uni-lamellar and spherical,
and ranging between 100 and 200 nm, with the presence of some larger
vesicles around 500 nm.
Table 4 shows a summary of the characterization results of the DoE
samples, which were considered for the statistical analysis. The three out of
ten batches (DOE-001, DOE-006, and DOE-009) that presented small se-
dimentation also showed a higher TSI indicating the dispersion instability.
Besides, samples in which aggregation and sedimentation were ob-
served presented also higher size and PdI, and lower uni-lamellarity.
Furthermore, the mean particle size and PdI of DOE-001, DOE-006, and
DOE-009 significantly increased with time after production (Appendix D).
On the other side, ζ-potential, EE, and EA values did not correlate with
macro and microscopical characteristics of the samples.
All the formulations showed enzymatic activity, varying from 0.8 to
1.7 ratio to control referred to the enzymatic activity of a commercially
available free GLA (Agalsidase alfa, Replagal® from Shire-Takeda) in-
cluded in the analysis, as also shown in Table 4. These results indicate
an excellent enzymatic activity in all cases, compliant with preliminary
specifications.
3.5. Analysis of the influence of the factors on CQAs
The influence of the factors was studied for the rest of dependent
variables or CQAs. An analysis and discussion for each quantifiable
CQA is described below. From the characterized CQAs, mean particle
size, ζ-potential, and uni-lamellarity could be statistically fitted and
were included in the prediction model (see Appendix E for modeling
and data fitting) while for the rest of attributes a bad correlation was
obtained and thus a poor predictive ability of the model.
According to the data presented in Table 4, the mean particle size of
the nanoGLA dispersions varied from 90 to 200 nm. These differences
could be explained because of the aggregation and fusion of liposomal
vesicles that could occur 1 week after preparation. The coefficients of
the equation describing the influence of the factors on nanoGLA particle
Table 2
Factors included in the DoE to optimize the intermediate nanoGLA formulation, their potential impact into CQAs and the ranges of investigation.
Factor Potential impact into CQAs Factor Range studied in DoE
GLA concentration Protein concentration plays a key role on dispersion stability. It
has been reported that increasing the loading and charge of
protein will impact on size distribution and aggregation rate of
the liposomal system [23].
From 7 to 27 µg/mL of enzyme. Defined according to the viability of
performing the subsequent diafiltration and concentration step up to
the 200 µg/mL required for in vivo doses.
Lipid concentration Besides the molar ratio between membrane components
(cholesterol and phospholipid), the total lipid concentration in
liposomal systems will impact on its mean size, particle
distribution and stability, as well as on its loading capacity
[24–27].
From 1.2 to 5.0 mg/mL, moving almost 2 mg/mL up and down of




PEGylation of liposomes improves not only the stability and
circulation time, but also the passive targeting ability on tumoral
tissues, through a process known as the enhanced permeation
retention effect, able to improve the therapeutic effects and
reduce the toxicity of encapsulated drug [28].
From 1% to 3% mol of molar ratio in relation to the total amount of
lipid components, according to previous studies.
EtOH concentration Solvent concentration could have a direct impact on shape,
solubility and electrostatic interactions between the liposomal
bilayer and the loaded protein [29].
From 5% to 10% v/v, folding the standard 5% v/v since higher
quantities are not recommended for intravenous administration [4].
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size are shown in Fig. 4a (left). According to this figure, the size of
nanoGLA liposomes is significantly influenced by GLA concentration
(X1) and the lipid concentration (X2). Thus, a significant increase in
size is obtained when the concentration of GLA and lipid increase. The
increase in size with the increase of GLA and lipid concentrations could
be explained by the occurrence of physical aggregation of the vesicles.
The influence of GLA and lipid concentration is also illustrated by the
contour plot for size in Fig. 4a (right).
As shown in Table 4, ζ-potential ranged from 32 to 46mV for non-
diafiltrated liposomes. The influence of studied factors on ζ-potential is
shown as coefficients of the regression equation plot in Fig. 4b (left).
According to this plot, lipid concentration (X2) was the only factor that
had a significant positive effect on the ζ-potential of the dispersions
obtained. This could be explained because when lipid concentration
increases, MKC surfactant (used as excipient in the nanoformulation)
concentration also increases, giving more positive charges to the lipo-
somal system. The influence of lipid concentration is also illustrated by
the contour plot for size in Fig. 4b (right).
Monolayered liposomes fractions varied from 0.88 to 1.00, as shown
in Table 4 by fsingle values. According to Fig. 4c (left), lipid con-
centration was the only factor affecting this CQA significantly, showing
a larger difference in comparison to the rest of factors. As can be seen in
Fig. 4c (right), GLA concentration had an insignificant influence on the
monolayer ratio of liposomes, but it was strongly affected by the lipid
concentration. The explanation can be the same as the effect of lipid
concentration on vesicle size: aggregation and fusion of the vesicles
when lipid concentration increases could be responsible of this
behavior.
Table 3
Matrix of experimental design. The sample codes consider the randomized order of experiments.
Experimental run GLA concentration (µg/mL) Lipid concentration (mg/mL) Chol-PEG400-RGD molar ratio to lipids
(% mol)
EtOH concentration (% v/v)
DOE-001 27 1.2 1 10.0
DOE-002 7 1.2 3 10.0
DOE-003 17 3.1 2 7.5
DOE-004 27 5.0 1 5.0
DOE-005 7 5.0 3 5.0
DOE-006 27 1.2 3 5.0
DOE-007 17 3.1 2 7.5
DOE-008 7 1.2 1 5.0
DOE-009 27 5.0 3 10.0
DOE-010 7 5.0 1 10.0
Fig. 3. Representative cryo-TEM images of nanoGLA DoE samples at 1 week after production. Scale bar 200 nm.
Table 4
Characterization of intermediate nanoGLA CQAs after 1 week of production. Uncertainties are calculated from the standard deviation of measurement for Size, PdI,
ζ-potential, and EE; and from standard error of the mean for uni-lamellarity and EA.
Sample ID Size (nm) PdI ζ-potential (mV) TSI Uni-lamellarity, fsingle EE (%) EA (ratio to control)
DOE-001a 143 ± 6 0.45 ± 0.08 35 ± 2 11.5 0.88 ± 0.01 60 ± 1 1.7 ± 0.1
DOE-002 88 ± 2 0.17 ± 0.01 36 ± 2 0.6 0.99 ± 0.01 53 ± 1 1.2 ± 0.0
DOE-003 142 ± 3 0.12 ± 0.05 34 ± 0 1.2 0.95 ± 0.00 59 ± 1 1.4 ± 0.0
DOE-004 175 ± 1 0.32 ± 0.05 45 ± 0 8.2 0.93 ± 0.00 45 ± 1 1.6 ± 0.1
DOE-005 158 ± 4 0.24 ± 0.03 45 ± 6 1.9 0.93 ± 0.00 42 ± 1 0.8 ± 0.1
DOE-006a 202 ± 4 0.46 ± 0.05 32 ± 1 6.6 0.85 ± 0.02 68 ± 1 1.5 ± 0.0
DOE-007 146 ± 2 0.11 ± 0.05 35 ± 1 1.2 0.99 ± 0.01 53 ± 1 1.2 ± 0.2
DOE-008 100 ± 1 0.17 ± 0.02 38 ± 1 1.8 1.00 ± 0.01 84 ± 1 0.8 ± 0.0
DOE-009a 172 ± 5 0.22 ± 0.02 38 ± 1 12.0 0.94 ± 0.01 53 ± 1 1.1 ± 0.1
DOE-010 134 ± 2 0.13 ± 0.02 46 ± 2 0.6 0.93 ± 0.00 84 ± 1 1.4 ± 0.1
a DOE-001, DOE-006, and DoE-009 presented sedimentation.
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3.6. Evaluation of the design space
Among all the factors studied, GLA concentration and lipid con-
centration were found to have a significant influence on some of the
responses. Thus, the Design Space for intermediate nanoGLA was con-
structed using these factors which significantly influenced the quality of
the nanoformulation. On the one hand, increase of GLA and lipid
concentration had a negative influence on liposomal mean particle size
because of the size increase promoted by aggregation. On the other hand,
as the lipid concentration increased, and, consequently, the amount of
MKC surfactant was higher, ζ-potential (which is related to the electrical
charge at the liposomes surface) also increased due to the formal positive
charge provided by this cationic surfactant. Nevertheless, this ζ-potential
increase was not correlated with a higher colloidal stability of the nano-
formulation as also confirmed by an uni-lamellarity decrease. It seems that
this MKC amount is not enough to stabilize such highly concentrated
samples. However, higher MKC concentrations, although could improve
the stability of these concentrated samples, it also could entail a
toxicological concern as well as the abolishment of the enzymatic activity
of the GLA, as reported by Tomsen-Melero et al. [7].
The other CQAs such as polydispersity index, TSI, GLA entrapment
efficiency, and enzymatic activity could not be fitted in any reliable model
because of the sedimentation of some batches and the high characterization
variability, due to the use of SDS-PAGE plus TGX as a reference method for
Fig. 4. Left side: scaled and centered coefficients of the regression equations describing the influence of formulation parameters X1-GLA concentration, X2-lipid
concentration, X3-Chol-PEG400-RGD molar ratio, X4-EtOH concentration, on the liposomes size, ζ-potential, and uni-lamellarity of nanoGLA intermediate dispersion.
Right side: contour plots for the same CQAs of the nanoGLA intermediate dispersion. Molar ratio of chol-PEG400-RGD to lipid and EtOH concentration were kept
constant at 2% mol and 7.5% v/v, respectively.
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GLA quantification. Results could be improved in the future using a HPLC
method for the quantification of GLA. Hence, the Design Space was de-
termined using particle size, ζ-potential, and uni-lamellarity.
The Design Space obtained is shown as the green region in Fig. 5,
and shows the combination of factors for which the nanoGLA inter-
mediate obtained by DELOS-susp will meet the specifications in terms
of CQAs, specified in Table 5, with a probability of failure less than 1%.
The combination inside the design space which is pointed out by the
black arrows indicates the robust setpoint (17.7 µg/mL GLA con-
centration, 2.97mg/mL lipid concentration, 1.3% mol Chol-PEG400-
RGD, and 6.2% v/v EtOH) corresponding to the formulation for which
the prediction errors are the lowest.
To our knowledge, there are no similar results reporting the
relationship between lipid and protein concentration affecting size,
ζ-potential, and uni-lamellarity in this way. We could expect that at low
concentration of lipid and GLA, we would also obtain a nanoGLA within
the established acceptance limits, so it could be possible that the red
zone showed in Fig. 5 around the lowest concentrations belongs to a
range that remained unexplored. In addition, the finding of a model
which indicates that formulation will escape from the acceptance limits
if both factor concentrations are high is due to aggregation effect of
liposomes caused by a change of interaction between them, provoked
by the high load of components in the membrane [24,31].
3.7. Optimization of the nanoGLA formulation
The challenge was to obtain a stable nanoGLA concentrated for-
mulation containing 200 μg/mL of GLA, suitable doses for in vivo
testing. To do so, a batch of nanoGLA was prepared by DELOS-susp and
diafiltrated and concentrated following the trend of the preliminary
Design Space: the lipid concentration was reduced to 1.2mg/mL so that
the GLA concentration could be increased up to 35 µg/mL, obtaining an
intermediate nanoGLA by DELOS-susp meeting all the CQAs.
Physicochemical properties are shown in Table 6 and Fig. 6. Particle
mean size, polydispersity index, ζ-potential, and GLA concentration –
all meet the requirements to go to future in vivo preclinical trials
(<300 nm, ≤0.45,>30mV, and>200 μg GLA/mL, respectively). A
good colloidal stability was observed for the concentrated final na-
noGLA, composed mainly by single lamellar liposomes (Fig. 6). Some
structural effects were noticeable by cryo-TEM after over-concentrating
the GLA-loaded liposomes. Images revealed the formation of some
multilamellar complexes, where the GLA can be identified between li-
posomal layers as well as inside the vesicles (Fig. 6, arrows), forming
structures resembling lipoplexes [32]. Interestingly, the high con-
centration of GLA (330 µg/mL) after the concentration process where
these structures were identified was quite above the minimum required
value for in vivo trials (200 µg/mL).
In addition, the final prototype dispersion was stable for more than
2 weeks.
Fig. 5. The Design Space for intermediate nanoGLA liposomal dispersion that meets the specifications in terms of CQAs, expressed as the probability of failure (%).
Molar ratio of chol-PEG400-RGD to lipid and EtOH concentration have been optimized in the run at 1.16% mol and 6.2% v/v, respectively.
Table 5
The desired CQAs of nanoGLA introduced in the Design Space explorer and
their values.
Response Criterion Min. Target Max.
Size (nm) Target 50 150 250
ζ-potential Excluded – – –
Uni-lamellarity (fsingle) Maximize 0.95 1.00 –
Table 6
Critical Quality Attributes for optimized intermediate nanoGLA, diafiltrated and concentrated around 10-fold.
Attributes After DELOS-susp (Intermediate nanoGLA) After concentration (Preclinical nanoGLA)
Stability NA >2 weeks
Particle mean size (nm) 138 ± 7 165 ± 3
Polydispersity Index 0.38 ± 0.03 0.41 ± 0.02
ζ-potential (mV) 40 ± 1 35 ± 1
Enzymatic activity (ratio to control) 1.11 ± 0.08 0.93 ± 0.04
GLA (µg/mL) 34 ± 2 330 ± 20
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3.8. Safe-by-Design implementation
The implementation of the SbD approach followed the strategy
reported by [33] and was specifically tailored to complement the QbD
work, to prevent hazards from the developed components and processes,
and to support the redesign of technical workflows where the need is
identified. Each individual process step was evaluated to identify possible
exposure scenarios and safety issues.
For the used DELOS-susp methodology (see Fig. 2), four specific
issues that pose a potential risk were identified:
1. DMSO/EtOH in the nanoformulation
2. Aerosol exposition due to organic compounds, vapors, streams from
the organic phase
3. Carbon dioxide poisoning
4. Cold burn during lyophilization
All the identified possible risks during the DELOS-susp methodology
are rated on low respectively medium risk level and are controlled
(see Appendix F), thus the DELOS-susp process can be considered as
safe. To fully cover the entire innovation process towards its final
product application, immunogenicity, endotoxicity, and impurities of
the nano-formulation will be evaluated at later stage.
4. Conclusions
The current work brings a new contribution in the preparation of GLA
loaded liposomes through the successful application of the QbD approach
to DELOS-susp production method. Thanks to this methodology a
prototype of nanoGLA suitable for in vivo testing could be optimized. The
influence of some formulation parameters was determined by using a
DoE. Thus, among the formulation factors, GLA concentration and lipid
concentration were the most important parameters for the quality of
nanoGLA obtained by compressed fluid processing.
This study also enabled the obtaining of a preliminary design space
to produce nanoGLA intermediate dispersion, in which the established
quality requirements of the product are met.
Through the design space analysis, it could be predicted that for
achieving a higher (10-fold), concentration of enzyme in the final for-
mulation the concentration of lipid in the DELOS-susp step could be
reduced in order to obtain a good quality product in terms of particle
size and uni-lamellarity, and to avoid aggregation and sedimentation.
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Appendix A. Synthesis of GLAcmycHis
Plasmids and E. coli strains
The GLA gene was obtained from the commercial vector pReceiver-M10 (OmicsLink ORF Expression Clone, ref. EX-Q0172-M10), that encodes a
cDNA version of the GLA gene (primary gene accession number: NM_000169), in which both c-myc and 6xHis tags are fused (for further detection
and purification purposes) to the C-terminus.
For further steps, the pOptiVEC™-TOPO® TA Cloning Kit (Catalog Number 12744-017, Invitrogen, by Life Technologies) was used following the
vendor protocol. The PCR product was cloned into the pOptiVEC™-TOPO® plasmid, and the resulting plasmid (pOptiVec-GLA) was transformed into
TOP10 E. coli cells. Positive clones were selected by ampicillin and confirmed by restriction analysis. The pOptiVec-GLA plasmid was purified by
“gigaprep” method, and finally linearized before transfection, as recommended by the vendor, with restriction enzyme PvuI. All plasmids were
purified from their corresponding overnight bacterial cultures, using the EndoFree Plasmid Giga Kit (Qiagen, ref. 12391). For their quantification,
absorbances at 260 nm (A260) and 280 nm (A280) were measured.
Mammalian cell line, transfection and selection of positive clones
For the transfection and further selection of CHO cells overexpressing the human GLA enzyme, the OptiCHO™ Express Kit (Catalog number
12745-014, Invitrogen, by Life Technologies) was used. This kit provides CHO DG44 cells, media and transfection reagent needed. DG44 dhfr- CHO
cells were grown in CD DG44 medium with 8mM L-glutamine, at 37 °C in 8% CO2 using standard techniques.
Transfection of CHO DG44 cells and selection of positive GLA-DHFR cells were performed following the vendor protocol. At 28 days
post-transfection, stepwise selection for dhfr amplification was started, using two-fold increments of methotrexate hydrate (MTX, Sigma, catalog
number A6770) starting at 50 nM up to 4 μM. Finally, and in order to obtain a single clone, the pool of stably transfected and 4 μM MTX-amplified
cells were serially diluted and seeded at 1–2 cells per well in a 96-well plate. As suggested by vendor, to grow CHO DG44 cells under adherent
conditions, the specific medium Gibco® CD-CHO-A was used. After this process, a single clone (namely CHO-DG44-GLA clone #3) was isolated and
cryopreserved.
Cryopreservation of CHO-DG44-GLA clone #3
CHO-DG44-GLA clone #3 was cultured in complete CD OptiCHO medium (supplemented with L-Glutamine 8mM) to 2×106 cells per milliliter
and then centrifuged at 100 g for 5min. Cell pellets were then resuspended in fresh medium containing 10% DMSO to a final cell concentration of
10×106 cells/mL. Cells were aliquoted into 1mL cryovials (Nalgene) and stored in the vapor phase of liquid nitrogen.
Production and purification of extracellular GLAcmycHis protein
Cryovials of CHO-DG44-GLA clone #3 were thawed under standard procedures. Briefly, cryovial was rapidly thawed at 37 °C and
resuspended in 15 mL of prewarmed complete CD OptiCHO medium. Cells were expanded by subculturing them up to the desired volume. In
each passage, cells were diluted into pre-warmed complete CD DG44 Medium to give a final cell density of 2× 105 –3× 105 viable cells/mL.
Finally, supernatant containing extracellular GLAcmycHis was harvested by centrifuging the cell culture at 14,000 rpm for 15 min. This su-
pernatant was purified in an ÄKTA Pure system (GE Healthcare) by using an affinity chromatography column (HisTrap Excel 5 mL,
Ref 17-3712-06, GE Healthcare) following the vendor protocol. Finally, the eluted protein was dialyzed in acetic buffer 0.01 M pH 5.5 and
stored at −20 °C until used.
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Appendix B. DELOS-susp methodology for the preparation of nanoGLA
Table B.1 summarizes the process parameters that were kept constant for all DELOS-susp experiments; and also includes the control strategies
since some of them could have an impact on some CQAs. The 10 experiments carried out in this study were produced in 2 consecutive days.
Appendix C. Risk analysis assessment
Fig C.1 represents a summary of Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs) that may impact the CQAs of the
intermediate nanoGLA using Ishikawa methodology.
Table B.1
DELOS process parameters kept constant in all DoE experimental runs.
Process Parameter Value Control
Working temperature, Tw 35 °C Heating jacket
High pressure stirring 500 rpm Magnetic stirrer controller
Working pressure, Pw 9MPa Syringe pump for CO2
Depressurization pressure in the autoclave 10MPa Manometer and N2 pressure regulator
Collector Stirring 300 rpm Plate with magnetic stirrer
CO2 molar fraction, XCO2 0.55 Solvent volume in the reactor
Depressurization flowrate 10 g/min Manually controlled due to scale, averaged











Dispersant media Column specs
Fig. C.1. Ishikawa diagram illustrating the summary of CPPs and CMAs that may impact on each selected CQA of intermediate nanoGLA dispersion.
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A control strategy is designed to ensure that a product of required quality will be produced consistently. These controls are based on product,
formulation and process understanding and should include, at a minimum, control of the critical process parameters and material attributes. The risk
assessment and the definition of control strategies serve to evaluate which CMAs and CPPs must be studied in a DoE.
In Table C.1 the risk analysis assessment of the potential CMAs and CPPs on the DELOS-susp process is presented.
Appendix D. Samples time evolution of mean particle size, PdI, and ζ-potential
Fig D.1 shows the analysis in time by DLS of the samples. As the Fig D.1. Evolution shows, the mean size of some samples increased during time,
mainly explained by the aggregation of the nanovesicles, showing clearly that DOE-006 and DOE-009 were going to sediment. PdI values, remained
constant except for the two samples previously mentioned. ζ-potential maintained mostly constant with time, although the decrease observed in
some cases could be explained because of the change in pH during time caused by the release of dissolved CO2.
Table C.1
Risk analysis assessment and control strategies of CMAs and CPPs for intermediate nanoGLA production by DELOS-susp.
CMA or CPP Impact on
CQA
Risk Control strategy
Components purity Low Change in composition CoA from supplier
Raw GLA High Change in morphology, nanoGLA
stability an activity
CoA from supplier and check analysis by TGX, BCA or HPLC.
Chol-PEG400-RGD AA% Low Affect biological activity CoA from supplier and check analysis
Chol-PEG400-RGD moisture Low Uni-lamellarity and morphology could
be affected.
CoA from supplier and check analysis
EtOH concentration High To be evaluated in DoE. To be included in DoE.
DMSO concentration Medium Stability, enzymatic activity Previously defined.
Buffer concentration Medium To be studied in further steps. To be defined in further steps of the project.
Membrane components molar
ratio
High Morphology, stability Previously defined.
Lipid concentration High Entrapment efficiency, stability of the
solution.
To be included in DoE.
Chol-PEG400-RGD concentration High Morphology, stability, intracellular
penetration
To be included in DoE.
MKC concentration High Higher concentration, higher stability
and Entrapment.
Previously defined.
GLA concentration High Stability, enzymatic activity To be included in DoE.
Mixing configuration High Morphology, stability Previously defined.
Operator Low Low control of the flowrate Lab scale: Follow the standard protocol and practice on
depressurization. Pilot scale: automatic control of depressurization
valve.
Stirring of vessel Low Enough to obtain a single phase inside
the high pressure vessel.
Previously defined, servocontrolled by high pressure stirrer.
Pressure of vessel Low Enough to obtain a liquid phase inside
the high pressure vessel.
Previously defined, servocontrolled by pump and PIC.
Temperature of vessel Low Enough to obtain a liquid phase inside
the high pressure vessel.
Previously defined, controlled by heating jacket and TIC.
CO2 molar fraction Low Inside the range of cosolvency. Previously Defined and controlled by volume, P and T of the pump.
N2 pressure Low 10 bar higher than pressure of the vessel,
could affect the flowrate.
Defined and controlled by a pressure regulator and PIC
Flowrate High Morphology and uni-lamellarity. To be
evaluated in DoE.
To be included in DoE.
Collector volume Medium Change in flow and mixing between
phases.
Previously defined.
Collector temperature High GLA degradation depends on
temperature and exposition time
Previously defined. Controlled by TIC.
Stirring of the collector Medium Change in flow and mixing between
phases.
Previously defined.
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Appendix E. Modeling and data fitting
The acceptance of the responses obtained was evaluated by means of the statistical parameters predicted by the software R2, Q2 model validity, and
model reproducibility: (i) R2: it represents the percent of the variation of the response explained by the model, that is, how well the model fits the data;
(ii) Q2: it is the percent of the variation of the response predicted by the model according to cross validation. It gives information about how well the
model predicts new data. In Table E.1, the values of these statistical parameters are summarized, indicating if the data collected from the experimental
results is fitting into a model. Only those CQAs that could be fitted (mean particle size, ζ -potential and uni-lamellarity) were included in the model.
Appendix F. Identified safety issues
Occupational exposure scenarios as well as environmental exposure scenarios were registered, considering different operational conditions.
Table F.1 shows the obtained risk rating key for the specific activity and/or process in the DELOS-susp methodology for the preparation of the
nanoGLA intermediate, and lists relevant methods to manage the possible risk and decrease its possibility to take place.
Fig. D.1. Evolution of a) mean particle size, b) PdI, and c) ζ-potential over time during 14 days after the production of the samples.
Table E.1
Statistical parameters and fitting for the investigated intermediate nanoGLA CQAs.
CQA R2 Q2 Fitting and model (if applies)
Mean particle size 0.937 0.661 Yes, Size = 2.0 X1 +10.6 X2 +11.7 X3 - 2.2 X4 +86
Polydispersity 0.437 0.200 No, a bad correlation and a poor predictive ability of the model were obtained.
ζ-potential 0.791 0.550 Yes, ζ-pot =−19 X1 + 2.1 X2 - 10.9 X3 - 24.5 X4 + 41
TSI 0.636 0.200 No, a bad correlation and a poor predictive ability of the model were obtained.
Uni-lamellarity 0.858 0.498 Yes, fsingle = 3.3·10−4 X1 - 1.8·10−2 X2 - 1.1·10−7 X3 - 5.7·10−9 X4 + 1.0
Entrapment efficiency 0.420 0.200 No, a bad correlation and a poor predictive ability of the model were obtained.
Enzymatic activity 0.625 0.040 No, it could be explained by the high measurement related variability
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Table F.1
Identified safety issues in relation to their severity and likelihood leads to risk rating key.










Preparation of the organic solution EtOH/DMSO in the
nanoformulation
Acceptable Low Related to the environment: Solvents to the non-
chlorinated solvents waste container. Cholesterol, Chol-
PEGn-RGD, MKC, and DPPC to the solid chemical waste
container.
LowAcceptable




Cleaning the laboratory material Related to workers: Fume hood. Mask, gloves, glasses and
lab coat.
Loading of the vessel, closing and
pressurization by adding CO2
Dermal/occupational safety
issues during loading the
vessel
Acceptable Low Related to workers: Fume hood. Mask, gloves, glasses, and
lab coat. Vent and safety valves present in the equipment
in case of overpressure
Preparation of aqueous solution Dermal safety issues during
cleaning of the material
Acceptable Low Related to workers: Fume hood. Mask, gloves, glasses, and
lab coat.
Depressurization and mixing of the
organic and aqueous phases
Carbon dioxide poisoning
during valve opening
Tolerable Low Related to workers: Fume hood. Mask, gloves, glasses and
lab coat. Vent and safety valves.
Filters for carbon dioxide exhaust expelled to the
environment have to be considered in larger scales.
Collecting the final product and storage Cold Burn during
lyophilization
Acceptable Low Fume hood. Mask, gloves, glasses and lab coat.
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